TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM313502

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE: SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Variation Biotechnologies (US), Inc.		07/25/2014	CORPORATION: DELAWARE
VBI Vaccines Inc.		07/25/2014	CORPORATION: DELAWARE
Variation Biotechnologies Inc.		07/25/2014	CORPORATION: CANADA

RECEIVING PARTY DATA

Name:	PCOF 1, LLC
Street Address:	499 Park Avenue
Internal Address:	25th Floor
City:	New York
State/Country:	NEW YORK
Postal Code:	10022
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark	
Serial Number:	76440352	VARIOSITE	

CORRESPONDENCE DATA

Fax Number: 7037607777

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

703-760-7360 Phone:

Email: trademark-dc@Mofo.com

Correspondent Name: Hsiao-Ting Cheng

Address Line 1: 1650 Tysons Boulevard

Suite 400 Address Line 2:


Address Line 4: McLean, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:	72295-3
NAME OF SUBMITTER:	Tomohisa Aiko
SIGNATURE:	/Tomohisa Aiko/
DATE SIGNED:	08/08/2014

Total Attachments: 6

TRADEMARK REEL: 005340 FRAME: 0387

900297845



TRADEMARK REEL: 005340 FRAME: 0388

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of July 25, 2014 (this "<u>Agreement</u>"), is made by Variation Biotechnologies (US), Inc., a Delaware corporation (the "<u>Borrower</u>") and the Guarantors party to the Credit Agreement (defined below); (the Borrower, the Guarantors are herein referred to as the "<u>Grantors</u>"), in favor of PCOF 1, LLC (together with its successors, transferees or assignees, the "<u>Secured Party</u>")...

WITNESSETH:

WHEREAS, pursuant to a Credit Agreement and Guaranty, dated as of the date hereof (as amended or otherwise modified from time to time, the "<u>Credit Agreement</u>"), by and among the Borrower, each Guarantor party thereto and the Secured Party, the Secured Party has extended Commitments to make Loans to the Borrower;

WHEREAS, in connection with the Credit Agreement, the Grantors have executed and delivered a Pledge and Security Agreement, dated as of the date hereof (as amended or otherwise modified from time to time, the "Security Agreement");

WHEREAS, pursuant to the Credit Agreement and pursuant to <u>clause (d)</u> of <u>Section 4.5</u> of the Security Agreement, each Grantor is required to execute and deliver this Agreement and to grant to the Secured Party a continuing security interest in all of the Trademark Collateral (as defined below) to secure all Obligations; and

WHEREAS, each Grantor has duly authorized the execution, delivery and performance of this Agreement; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Secured Party, as follows:

- SECTION 1. <u>Definitions</u>. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Security Agreement.
- SECTION 2. <u>Grant of Security Interest</u>. Each Grantor hereby grants to the Secured Party a continuing security interest in all of the following property, whether now or hereafter existing or acquired by such Grantor (the "<u>Trademark Collateral</u>"):
- (a) (i) all of its trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers of such Grantor, and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired including those referred to in Item A of <a href="Schedule I, whether currently in use or not, all registrations and recordings thereof and all applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America or any State thereof or any other country or political subdivision thereof or otherwise, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the "Trademark");
- (b) all Trademark licenses for the grant by or to such Grantor of any right to use any Trademark, including each Trademark license referred to in <u>Item B</u> of <u>Schedule I</u>;

1

- (c) all of the goodwill of the business connected with the use of, and symbolized by the items described in, <u>clause (a)</u>, and to the extent applicable <u>clause (b)</u>;
- (d) the right to sue third parties for past, present and future infringements of any Trademark Collateral described in <u>clause (a)</u> and, to the extent applicable, <u>clause (b)</u>; and
- (e) all Proceeds of, and rights associated with, the foregoing, including any claim by such Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world.
- SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantors for the purpose of registering the security interest of the Secured Party in the Trademark Collateral with the United States Patent and Trademark Office and corresponding offices in other countries of the world. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to the Secured Party under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Party thereunder) shall remain in full force and effect in accordance with its terms.
- SECTION 4. Release of Liens. Upon (i) the Disposition of Trademark Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Trademark Collateral (in the case of clause (i)) or (B) all Trademark Collateral (in the case of clause (ii)). Upon any such Disposition or termination, the Secured Party will, at the Grantors' sole expense, deliver to the Grantors, without any representations, warranties or recourse of any kind whatsoever, all Trademark Collateral held by the Secured Party hereunder, and execute and deliver to the Grantors such Documents as the Grantors shall reasonably request to evidence such termination.
- SECTION 5. <u>Acknowledgment</u>. Each of the Grantors does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.
- SECTION 6. <u>Loan Document</u>. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.
- SECTION 7. <u>Counterparts</u>. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement.

* * * * *

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

()

By:

Name: Jeff Baxter

Title: Chief Executive Officer

VBI VACCINES INC

By:

Name: Jeff Baxter

Title: Chief Executive Officer

VARIATION BIOTECHNOLOGIES INC

By:

Name: Jeff Baxter

Title: Chief Executive Officer

PCOF 1, LLC

Name:

Title: Wat Credit

By:

Name: Šam Chawla

Title: Portfolio Manager

SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT



1740 Woodroffe Ave., Bidg 400 Ottawa, Ontario, Canada K2G 3R8 813,749,4200 T 813,738,4178 F

Schedules to Trademark Security Agreement

	Variation Owned Trademark Applications				
Trademark Family: Variosite™					Priority Date: August 11, 2010
Country	Number	Agent	Filing Date/ Registration Date (Dd/mm/yr)	Reference No.	Status
Canada	S.N. 1,491,977	BLG	11/08/2010 (Filing date)	TM 102449-1 CA	Pending
US	S.N. 76/440,352	BLG	11/02/2002 (Priority filing date)	TM 54051-2 US	Pending
			09/08/2002 (Filing date)		
Mexico	S.N. 1,027,921 (Class 5)	BLG	19/08/2009 (Filing date)	TM 100380C5-21	Registered
	R.N. 1120583		11/09/2009 (Registration Date)		
Mexico	S.N. 1,027,927 (Class 42)	BLG	19/08/2009 (Filing date)	TM 100380C42- 21	Registered
	R.N. 1120585		11/09/2009 (Registration Date)		
EU	S.N. 2,823,367 R.N. 2,823,367	BLG	09/08/2002 (Filing date)	TM 54051-81	Registered
			12/03/2004 (Registration Date)		

REEL: 005340 FRAME: 0393



Trademar Lipid Partio	k Family: cle Vaccine [™]				Priority Date: May 20, 2011
Country	Number	Agent	Filing Date Dd/mm/yr	Reference No.	Status
Canada	S.N. 1,528,640	BLG	20/05/2011	TM 103841-1 CA	Pending
Trademar LPV™	k Family:				Priority Date: May 20, 2011
Country	Number	Agent	Filing Date Dd/mm/yr	Reference No.	Status
Canada	S.N. 1,528,635	BLG	20/05/2011	TM 103842-1 CA	Pending

2 | Confidential

RECORDED: 08/08/2014

TRADEMARK REEL: 005340 FRAME: 0394